Aeon BDx Advantage Blood Diagnostic Testing Service

Feb 23, 2017

Authentidate Holding subsidiary Aeon Global Health has added the BDx Advantage Blood Diagnostic testing service to its portfolio. The service menu includes metabolic, hepatic, and renal function testing; advanced lipid profiles; and general chemistry and extensive hormone testing. All testing will be run through the company's Roche Cobas 6000 high-throughput chemistry analyzer, the company said.

More Like This

Oct 15, 2018

Roche NGS Avenio Tumor Tissue Analysis Kits

Roche has launched three next-generation sequencing Avenio tumor tissue analysis kits for oncology research: the Avenio Tumor Tissue Targeted Kit, Expanded Kit, and Surveillance Kit. The new kits complement the company's NGS ctDNA kits. They use formalin-fixed paraffin-embedded tissue and have a workflow of five days. The Avenio Tumor Tissue Targeted Kit covers 17 genes to identify guideline-related biomarkers. The Avenio Tumor Tissue Expanded Kit is a 77-gene assay with both guideline-related and emerging biomarkers. The Avenio Tumor Tissue Surveillance Kit covers 197 genes and is intended for establishing a baseline for variants in longitudinal tumor burden monitoring.

Oct 11, 2018

Pacific Biosciences Sequel System 6.0

Pacific Biosciences has launched updates to its Sequel sequencing system, including software version 6.0, reagents version 3.0, and SMRT cells 1M v3. Together, these changes, which are part of the Sequel System 6.0 release, result in sequence reads with greater than 99 percent accuracy, throughput of up to 50 gigabases per SMRT cell, and average read lengths of up to 100 kilobases, depending on the insert size, the firm said. For amplicon sequencing and RNA sequencing, customers can generate up to 500,000 reads with single-read accuracy greater than 99 percent. For whole-genome sequencing, customers can generate up to 20 gigabases of data per SMRT cell, with average read lengths of up to 30 kilobases.

Oct 11, 2018

Cellecta CloneTracker XP Expressed Lentiviral Barcode Library and Barcoded CRISPR Library

Cellecta has launched the CloneTracker XP Expressed Lentiviral Barcode Library and CloneTracker XP Barcoded CRISPR Library product lines. The new CloneTracker XP Barcode Libraries differ from Cellecta's standard CloneTracker Barcode Library in that the unique DNA sequence is designed to express on an RNA transcript in the cells. The libraries can therefore be detected by either DNA or RNA sequencing. Researchers can use these libraries to label several million cells each with a unique barcode, subsequently performing NGS to sort out sub-populations of progeny cells derived from the original progenitors at any point during the experiment.

Additionally, a variation of the new CloneTracker XP barcode labeling product introduces a gene effector, in this case CRISPR sgRNA, into the barcode library. Each effector targets and disrupts a specific gene in each of the cells that pick up a barcode. In combination with cell-specific barcode tracking, this knockout helps researchers see how specific genetic disruptions change the cells' characteristics while simultaneously identifying the genetic pathways that are activated to produce them. The firm offers two small, pre-made CloneTracker XP Barcoded CRISPR knockout libraries targeting 27 human and mouse anti-cancer genes, as well as custom library development services for CloneTracker XP Barcoded CRISPR Libraries. The CloneTracker XP Expressed Barcode Libraries are available with barcodes expressed in the 3′- or 5′-UTR of an RNA transcript, and with fluorescent or chemiluminescent reporters.

Oct 11, 2018

Paragon Genomics CleanPlex UMI Lung Cancer Panel

Paragon Genomics will introduce its research-use-only CleanPlex UMI Lung Cancer Panel at the upcoming American Society of Human Genetics Meeting. The panel is a targeted resequencing assay designed for the detection of ultralow-frequency variants across the hotspot regions of 23 genes frequently associated with lung cancer. The CleanPlex UMI technology incorporates unique molecular identifiers that distinguish between the two strands of DNA, enabling correction of PCR and sequencing errors to achieve more accurate results. The product can be used to prepare sequencing-ready libraries in a single-tube format in 3.5 hours, and variants at 0.1 percent allele frequency can be detected with high specificity using only 30 ng of DNA, Paragon said. CleanPlex NGS Panels are available for use with Illumina or Life Technologies Ion Torrent platforms.

Oct 10, 2018

Oxford Nanopore 'Rev D' Flow Cells

Oxford Nanopore Technologies has released a new version of the flow cell for the MinIon and GridIon sequencers that include the 'Rev D' ASIC. The new flow cells can be used for a longer time and yield up to 30 gigabases of data.

Oct 10, 2018

Oxford Nanopore MinIT

Oxford Nanopore Technologies has launched the MinIT, a compute module for use with the MinIon sequencer. MinIT is equipped with a Nvidia AGX system for real-time high-throughput data analysis and is preconfigured with software for MinIon set up and operation. Users can operate the module using either a tablet or mobile phone. MinIT runs both the instrument software MinKnow and the real-time analysis platform for nanopore data EPI2ME. Customers can power the tool using battery packs, which are available separately.

Oct 10, 2018

L7 Enterprise Science Platform 2.0

L7 Informatics, formerly known as Lab7 Systems, has introduced version 2.0 of its Enterprise Science Platform, featuring a validated, pre-built connection to the Microsoft Genomics service so users can run bioinformatics pipelines on the Microsoft Azure cloud. The release also includes workflow chaining to support multivariable processes, as well as support for next-generation sequencing, translational research, and cell therapy applications, plus a new user interface.

Oct 09, 2018

MDNA Life Sciences Mitomic Prostate Test

MDNA Life Sciences has announced the UK release for its PCR-based Mitomic Prostate Test (MPT). The MPT is a liquid biopsy assay optimized for the early detection of prostate cancer in advance of biopsy. The firm designed the MPT for testing men with clinical suspicion of prostate cancer to determine their likelihood of clinically significant cancer that may benefit from rapid intervention. The test will run on MDNA's CE-IVD kit, which contains the needed reagents to process up to 21 patient samples at a time.

Oct 05, 2018

Stratify Genomics Prompt Prostate Cancer Test

Stratify Genomics has announced Prompt, its new lab-developed test to track a man's genetic predisposition to prostate cancer. According to the firm, Prompt incorporates genetic information from several prostate cancer-risk associated SNPs. Using population-based analyses, the test reports how many men (out of 100) with a given genetic score would go on to develop prostate cancer. Clinicians can perform the test with a cheek swab sample to help men know their individual risk and potentially identify high-risk individuals.

Oct 04, 2018

Precipio HemeScreen

Precipio this week commercially launched HemeScreen, a test for mutations in hematologic cancers. The test measures for mutations in the CALR, JAK2, JAK2 exon 12, and MPL genes, which are critically important to developing the clinical roadmap for the patient, Precipio said. The company will offer the assay through its CLIA laboratory in New Haven, Connecticut, and will also offer a set of RUO reagents to other reference labs to perform the test in their CLIA laboratories.

Oct 03, 2018

Seq2Know Celiac Disease Testing

Seq2Know has begun offering celiac disease testing. The firm's test includes the sequencing of the DQA1 and DQB1 genes that have been associated with celiac disease. All tests will be ordered directly from Seq2Know.com and will be reviewed by PWNHealth to ensure the appropriateness of the test, the company said. 

Sep 28, 2018

MNG Xpress Exome

MNG Laboratories has launched the MNG Xpress Exome, a diagnostic exome sequencing test to identify mutations in Mendelian disorders. The test, which has a turnaround time of 10 to 14 days, costs $4,895 for a trio and $3,295 for proband-only testing.

Sep 28, 2018

Horizon Discovery Myeloid DNA Reference Standard

Horizon Discovery launched its Myeloid DNA Reference Standard, a large cell-line derived myeloid cancer reference standard designed to enable faster, more reliable, and more cost-effective assay validation. The Myeloid DNA Reference Standard is latest addition to the company's portfolio of more than 100 reference standards, and has been developed using Horizon's specialist gene editing technology to contain 22 mutations across 19 genes that are commonly associated with myeloid cancer. This provides genetic testing laboratories and assay developers with a tool to effectively validate and optimize myeloid genetic tests with DNA of known genotype which closely mimics the genomic DNA format and mutations present in real patient samples. The Myeloid DNA Reference Standard contains variants in more genes than most clinical material, enabling quality assurance goals to be reached faster, the firm noted.

Sep 28, 2018

Sysmex Inostics OncoBeam EGFR Kit V2

Sysmex Inostics, a subsidiary of Sysmex, has launched the OncoBeam EGFR Kit V2 for research use only in Europe and Asia. Replacing the firm's EGFR V1 kit, the V2 kit features workflow improvements, such as minimizing hands-on time and increasing efficiency. In addition, the kit covers substantially more mutations in the EGFR gene than its predecessor.

Sysmex's tool employs the firm's BEAMing technology to detect 36 cancer-relevant EGFR mutations present in ctDNA extracted from plasma, including sensitizing mutations like exon 19 deletions and L848R, as well as the T790M resistance mutation and multiple C797S variants. The assay combines emulsion-based PCR with flow cytometry to provide sensitive detection of rare mutant molecules. According to the firm, the assay requires a minimum of 2 ml of plasma to quickly deliver a comprehensive view of EGFR mutation status across all tumor cells. 

Sep 24, 2018

Roche FoundationOne Liquid

Roche has globally launched Foundation Medicine's FoundationOne Liquid, a liquid biopsy test that can identify 70 of the most commonly mutated genes in solid tumors, as well as microsatellite instability. The test complements FoundationOne CDx, the company's tissue-based genomic profiling test, and is different from FoundationAct, the firm's first liquid biopsy assay, which analyzed 62 genes and did not report MSI.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.